XM does not provide services to residents of the United States of America.

Health insurers unveil Medicare Advantage plans for 2025



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Health insurers unveil Medicare Advantage plans for 2025</title></head><body>

Adds details from Centene and Humana's plans in paragraphs 6 and 9

Oct 1 (Reuters) - Health insurers Cigna CI.N, CVS Health CVS.N, Humana HUM.N and Centene CNC.Non Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above.

The announcements come ahead of the beginning of enrollment for Medicare Advantage plans on October 15, which will continue through December 7.

Medicare Advantage plans are offered by private insurers who are paid a set rate by the U.S. government to manage healthcare for older people looking for extra benefits not covered in regular Medicare coverage.

Cigna said it will offer some prescription drug plans with low premiums that will help save costs.

CVS' health insurance unit Aetna estimates 83% of Medicare-eligible beneficiaries in the United States will have access to a $0 monthly premium plan.

Humana, which has a total of 793 individual Medicare Advantage plans across the country for next year, said all plans that provide coverage for prescription drugs will see some benefit enhancements in 2025 under the Inflation Reduction Act.

The health insurerswill also offer special needs plans, where individuals are enrolled under Medicare and receive assistance from Medicaid that covers medical expenses for people with low income.

The companies will provide dental, hearing and vision coverage as well.

Centene said it will offer $0 copay for primary care physician visits on all plans and for certain drugs at preferred pharmacies for most plans.

Medicare Advantage plan enrollment is projected to grow to 35.7 million people in 2025, the Centers for Medicare and Medicaid Services said on Friday.



Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.